Elimination of amrinone during continuous veno-venous haemofiltration after cardiac surgery.
We studied the elimination of amrinone during continuous veno-venous haemofiltration (CVVHF) in three anuric patients after cardiac surgery. The patients had developed low cardiac output followed by acute prerenal failure. Plasma amrinone levels measured by HPLC were fitted to a two-compartment model. We found significant amrinone clearance, with a mean sieving coefficient (S) of 0.44%, which correlates with the protein-unbound, pharmacologically effective fraction of amrinone. The AUC of the arterial plasma concentration-time curve was decreased by 49.8%. All pharmacokinetic parameters showed wide interindividual variation. To ensure the therapeutic effect of amrinone and to avoid toxic adverse effects monitoring of plasma amrinone levels is necessary.
Hellinger
A
A
Department of General Surgery, University of Essen, Germany.
Wolter
K
K
Marggraf
G
G
Pentz
R
R
Fritschka
E
E
D000676:Amrinone / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D001002:Anuria / Q000378:metabolism; D002302:Cardiac Output / Q000502:physiology; D006348:Cardiac Surgical Procedures; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006207:Half-Life; D006440:Hemofiltration; D006801:Humans; D008875:Middle Aged
D000676:Amrinone